← Scroll for more →
Financial Statements — PRZO
Balance Sheet
(in millions USD)| Metric | Q4 2025 | Q2 2025 | Q4 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.16 | 2.37 | 4.18 | 7.43 | 0.08 |
| Short-term Investments | 2.00 | 2.50 | -- | -- | -- |
| Accounts Receivable | 0.19 | 0.04 | 0.11 | 0.02 | 0.02 |
| Inventory | 0.20 | 0.34 | 0.39 | 0.26 | 0.34 |
| Total Current Assets | 4.83 | 5.79 | 5.11 | 8.37 | 0.96 |
| Property, Plant & Equipment | 0.11 | 0.11 | 0.11 | 0.05 | 0.03 |
| Total Non-current Assets | 0.47 | 0.54 | 0.63 | 0.06 | 0.06 |
| Total Assets | 5.31 | 6.33 | 5.74 | 8.42 | 1.02 |
| Accounts Payable | 0.00 | -- | 0.00 | 0.00 | -- |
| Total Current Liabilities | 1.33 | 1.24 | 1.32 | 0.76 | 3.00 |
| Total Non-current Liabilities | 0.82 | 1.57 | 4.73 | 1.56 | 0.41 |
| Total Liabilities* | 2.15 | 2.80 | 6.05 | 2.32 | 3.00 |
| Retained Earnings | -- | -- | -- | (1.60) | 2.00 |
| Total Stockholder Equity | 3.16 | 3.53 | (0.31) | 6.11 | (1.97) |
← Scroll for more columns →
* Derived from reported values
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2025 | Q2 2023 |
|---|---|---|
| Total Revenue | 0.36 | 0.34 |
| Cost of Revenue | 0.43 | 0.19 |
| Gross Profit | (0.07) | 0.15 |
| Research & Development | 1.16 | 0.22 |
| Selling, General & Admin | 1.67 | 0.10 |
| Total Operating Expenses | 3.58 | 0.52 |
| Operating Income | (3.65) | (0.37) |
| Net Income | (2.30) | (0.43) |
| Basic EPS | (0.14) | 0.12 |
| Diluted EPS | (0.14) | 0.12 |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q2 2025 | Q2 2023 |
|---|---|---|
| Operating Cash Flow | (3.07) | (0.25) |
| Capital Expenditures | 0.02 | 0.00 |
| Free Cash Flow* | (3.09) | (0.25) |
| Investing Cash Flow | (2.53) | -0.00 |
| Financing Cash Flow | 3.79 | 0.25 |
← Scroll for more columns →
* Derived from reported values